Compare SPT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | EVO |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.9M | 1.1B |
| IPO Year | 2019 | 2021 |
| Metric | SPT | EVO |
|---|---|---|
| Price | $11.45 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $26.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.0M | 253.9K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $443,750,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $13.30 | N/A |
| Revenue Next Year | $11.37 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.09 | N/A |
| 52 Week Low | $9.16 | $2.84 |
| 52 Week High | $35.18 | $4.80 |
| Indicator | SPT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 50.78 |
| Support Level | $10.97 | $3.03 |
| Resistance Level | $12.06 | $3.18 |
| Average True Range (ATR) | 0.45 | 0.08 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 62.62 | 83.87 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.